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ABSTRACT: Recombinant adeno-associated viruses (AAVs) are promising
vectors for human gene therapy. However, current methods for evaluating
AAV particle populations and vector purity are inefficient and low resolution.
Here, we show that charge detection mass spectrometry (CDMS) can resolve
capsids that contain the entire vector genome from those that contain partial
genomes and from empty capsids. Measurements were performed for both
single-stranded and self-complementary genomes. The self-complementary
AAV vector preparation appears to contain particles with partially truncated
genomes averaging at half the genome length. Comparison to results from
electron microscopy with manual particle counting shows that CDMS has no
significant mass discrimination in the relevant mass range (after a correction for the ion velocity is taken into account). Empty
AAV capsids are intrinsically heterogeneous, and capsids from different sources have slightly different masses. However, the
average masses of both the empty and full capsids are in close agreement with expected values. Mass differences between the
empty and full capsids for both single-stranded and self-complementary AAV vectors indicate that the genomes are largely
packaged without counterions.
There has been growing interest in using native massspectrometry to investigate protein complexes and other
assemblies including viruses, with masses into the MDa
range.1−4 However, there are challenges associated with the
mass analysis of such large objects. The main issue is that the
peaks in the m/z spectrum broaden and shift due to mass
heterogeneity, either intrinsic or due to adduct formation.
Poorly resolved peaks in the m/z spectrum prevent charge state
assignment and subsequent mass deduction. In particular,
viruses have a proclivity for being heterogeneous in mass
because they have the ability to encapsidate varying amounts of
genetic material. Earlier studies demonstrated the feasibility of
using time-of-flight mass spectrometry to measure the m/z
spectrum of the ∼2.5 MDa bacteriophage MS2 capsid, albeit
without sufficient charge state resolution to calculate an
accurate mass.5 More recently, high resolution m/z spectra of
empty hepatitis B virus (HBV) capsids assembled from proteins
lacking the C-terminal RNA-binding domain have been
reported.6 However, the m/z spectrum for HBV assembled
from the full-length capsid protein lacked charge state
resolution due to heterogeneity in the amount of packaged
RNA.7 For human rhino virus, incipient charge state resolution
was obtained for the empty HRV-A2 capsid allowing a mass
(5,210 kDa) to be assigned. On the other hand, for wild type
HRV-A2 (with RNA), charge state resolution was absent, so its
mass could not be determined from the m/z spectrum.8
Charge detection mass spectrometry (CDMS) bypasses the
need to resolve charge states. CDMS is a single particle
technique, where the m/z and z of individual ions are measured
concurrently, thereby allowing direct determination of the mass
of each ion.9−14 CDMS can analyze heterogeneous mixtures of
protein complexes and other large assemblies that are
intractable by conventional MS methods.15−17 In the studies
reported here we have used CDMS to determine the DNA
content of recombinant adeno-associated viral (AAV) vectors.
AAV vectors have emerged at the forefront of gene therapy
due to their lack of pathogenicity, relatively low immunoge-
nicity and persistent gene expression in different tissue types.18
From a structural perspective, this helper-dependent parvovirus
has a nonenveloped, icosahedral capsid ∼25 nm in diameter
that packages a single-stranded DNA (ssDNA) genome ∼4.7kb
in length.19 Despite promising outcomes, a recurring concern
noted in hemophilia gene therapy clinical trials is the potential
for vector dose-related immunotoxicity in patients.20 Although
resolvable by administration of anti-inflammatory steroids such
as methyl prednisolone, several studies have indicated that the
composition of clinical AAV vector preparations can influence
these outcomes.21,22 In this regard, it is well-known that
recombinant AAV vector preparations can contain different
levels of full or partial genome-containing particles as well as
empty capsids.23,24 Such particle diversity can be attributed to
multiple factors such as genome packaging efficiency,
production methods, downstream purification techniques and
storage conditions.21,24
Though AAV packages ssDNA, the use of a self-
complementary (sc) DNA genome bypasses the rate-limiting
second-strand synthesis process and leads to more efficient and
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rapid onset of transgene expression.25−27 scDNA is formed by
joining two sequence-inverted vectors by a hairpin, so the
effective length of the unique transgene sequence is halved.
scDNA is packaged in a single-stranded form, but upon release
into the host cell, the two sequence-inverted regions can
undergo intramolecular base pairing and anneal into a base-
paired form. Though scAAV vectors show promise in the clinic,
characterization of their heterogeneous packaging behavior
remains a challenge due to the potential for contamination
from vectors packaging fragmented or truncated genomes.28
Currently, electron microcopy (EM) and qPCR are used in
combination to characterize the ultrastructural composition of
AAV vector preparations. While EM can easily distinguish
empty capsids from particles containing a full genome, it is
much more challenging to characterize particles containing
partial or truncated genomes. In particular, EM cannot
accurately determine the size of partial genomes. It is also
important to note that current quantitative PCR-based
methods, although robust and accurate, cannot help distinguish
partial or truncated vector genomes from fully packaged
genomes.29,30 Thus, the development of cutting edge methods
that can help analyze ultrastructural heterogeneity in
recombinant AAV vector preparations at high resolution is an
unmet need in the gene therapy field. Other techniques, such as
fluorescence-based thermal shift assays and dynamic light
scattering, as well as analytical ultracentrifugation, are being
explored as low-resolution techniques for the characterization
of recombinant AAV vectors.28 Here, we report proof of
principle studies showing that charge detection mass
spectrometry can be used to analyze AAV vectors (packaging
both single-stranded and self-complementary genomes). We
show that CDMS can quantitatively characterize diverse AAV
particle populations including particles packaging the complete
genome, empty particles, particles packing partial genomes, and
particles with impurities. A number of different naturally
occurring AAV serotypes have been described.31−33 They differ
primarily in the surface properties of the capsid and show
tropism for different tissue types. The studies described here
were performed with AAV serotype 8 (AAV8).
■ METHODS
AAV Vector preparations. All recombinant AAV vectors
were generated at the UNC Vector Core Facility. AAV8 vectors
packaging an ssDNA genome with a chicken beta-actin (CBA)
promoter driving a firefly luciferase transgene (Luc) or a
scDNA genome with a hybrid chicken beta-actin (CBh)
promoter driving a green fluorescent protein (GFP) transgene
flanked by AAV2 inverted terminal repeats (ITRs) from 3 to 4
different production runs were individually purified using a
discontinuous iodixanol gradient, followed by ion exchange
chromatography.34,35 Titers were obtained by qPCR with
primers specific for the Luc transgene. Separate fractions of
purified empty and genome-containing capsids were further
dialyzed into 100 mM ammonium acetate for CDMS analysis.
Charge Detection Mass Spectrometry. Mass analysis
was performed using a home-built charge detection mass
spectrometer that has been described previously.36−40 AAV
ions were generated by nanoelectrospray using an automated
TriVersa NanoMate system (Advion Inc., Ithaca, NY) and
transported into the vacuum chamber through a heated
stainless-steel capillary. The ions were separated from the
background gas by passing them through three differentially
pumped regions containing an RF ion funnel, an RF hexapole,
and an RF quadrupole, respectively. They are thermalized by
collisional cooling in the hexapole region. A DC voltage on the
hexapole reaccelerates them to ∼100 eV per charge (z) before
they enter a fourth differentially pumped region where they
were focused into the entrance of a dual hemispherical
deflection analyzer (HDA). The dual HDA passes a narrow
band of ion kinetic energies (centered on 100 eV/z) into the
fifth differentially pumped region that contains an electrostatic
ion trap with a cylindrical charge detection tube. With each
oscillation in the trap, the ion passes through the detector tube.
The induced charge is detected by a cryogenically cooled JFET
(2SK152) and then amplified with a charge-sensitive
preamplifier (Amptek A250). The periodic signals resulting
from ion oscillation are digitized and sent to a computer for
offline analysis using fast Fourier transforms. The oscillation
frequency of the ions is related to the m/z and the magnitude
of the fundamental is proportional to the ion charge. Charge
and m/z of individual ions are multiplied to give m. Only ions
that remain trapped for the entire trapping event (94 ms in this
study) are compiled and binned to create a mass histogram.
The uncertainty in the charge measurement in CDMS is a
function of the trapping time and oscillation frequency (and
hence the m/z). Here, we used a trapping time of 94 ms, which
leads to a charge uncertainty (RMSD) of ∼1.2 e for an AAV
capsid with an average m/z of ∼24 000 Da. For an average
charge of ∼155 e the relative uncertainty in the charge is
∼0.8%. The relative uncertainty in the m/z measurement
(∼0.8%) depends primarily on the ions’ kinetic energy
distribution. Typically, masses for 2−3 thousand ions are
required to characterize a sample and these measurements can
usually be performed in around 2 h with the nanomolar particle
concentrations employed here.
Electron Microscopy. 300-μm mesh carbon-coated copper
transmission electron microscopy grids were prepared by
spotting ∼3 uL of AAV8 (1012 vg/mL) on the entire grid area
for ∼1 min. Grids were washed with HPLC-grade water and
subsequently stained with 2% uranyl acetate for 1 min. After
drying, grids were imaged using a JEOL 1010 transmission
electron microscope. At least 2 images for each grid were taken
for qualitative analysis and up to 12 images of each grid were
taken for quantitative analysis.
■ RESULTS AND DISCUSSION
The AAV capsid has icosahedral symmetry and it is assembled
from 60 copies of the capsid viral protein (VP). There are three
different VPs: VP1, VP2, and VP3. VP1 is the longest, and for
AAV8 it consists of 738 residues. The VP2 sequence is identical
to VP1 except that 137 residues are truncated from the N-
terminus. In a similar way, the VP3 sequence is identical to VP2
except that 66 residues are truncated from the N-terminus. The
numbers of copies of VP1, 2, and 3 in each capsid are stochastic
with an average ratio of around 1:1:10 (i.e., the numbers of
VP1, 2, and 3 are random with an average of five copies of VP1,
five copies of VP2, and 50 copies of VP3, and a total of 60 VPs
altogether).41−46 The masses of AAV8 VP1, 2, and 3,
determined from their sequences, are 81,624, 66,649, and 59
762 Da,47−49 respectively, so the average mass of the empty
capsid is expected to be 3.729 MDa. Note that there will be a
distribution of masses due to variations in the numbers of VP1,
2, and 3 in each capsid. We consider this distribution further
below.
In the preceding paragraph we determined the expected mass
for the empty AAV8 capsid, we now compare this to the
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measured mass distribution for empty capsids. Figure 1a shows
a typical CDMS mass spectrum for empty capsids separated
from AAV8 vectors with a CBA-Luc genome. There is a large
peak centered on ∼3.8 MDa and a small high mass tail. CDMS
is a single particle technique and so the charge and mass can be
correlated. The points that overlay the main peak in Figure 1a
are a scatter plot of the charge and mass of each ion. The
charge distribution for the main peak shows a single
component centered on ∼155 elementary charges (e).
The inset in Figure 1a shows an expanded view of the
measured peak (black line). The red line shows a simulation of
the peak expected for a homogeneous sample of capsids
consisting of only VP3 (the lightest VP). This illustrates the
peak shape expected for a capsid with a single mass. The width
of the peak, ∼ 97 kDa full width at half-maximum (fwhm),
results from the uncertainties in the m/z and z measurements,
which are well characterized (see Methods section).36−40
Combining the relative uncertainties from the charge and m/
z leads to an overall relative uncertainty in the mass of ∼1.1%.
Note that this is the uncertainty associated with a single mass
measurement. For many independent mass measurements the
uncertainty leads to the peak width. The average mass (the
center of the peak) can be defined more accurately than the
uncertainty associated with a single mass measurement.
The blue line in the inset in Figure 1a shows the simulated
peak for a stochastic mixture of VP1, 2, and 3 in the expected
1:1:10 ratio. To calculate this peak, we first determined the
masses and abundances of all possible VP1, 2, and 3
compositions from a multinomial distribution. The resulting
mass distribution is shown in Figure 1b. The peaks in Figure 1b
are too close in mass to be resolved by CDMS with the
conditions employed here. When we account for the
uncertainties in the m/z and z measurements we obtain the
blue Gaussian peak in the inset of Figure 1a. The peak is
centered on 3.729 MDa, and it is around 152 kDa wide
(fwhm). It is considerably broader than the peak for the
homogeneous sample (red line) because of the distribution of
VP1, 2, and 3 compositions that are present.
The heterogeneous mass distribution in Figure 1b is a
challenge to analyze by conventional mass spectrometry
because each peak in the mass distribution would lead to a
number of overlapping peaks in the m/z spectrum (due to ions
in different charge states). However, Heck and co-workers have
made some progress in analyzing the m/z spectrum of AAV1
albeit with a sample that is less heterogeneous than the
expected 1:1:10 ratio and depleted in VP1.50 It is likely that
different expression systems yield AAV particles with different
compositions. For instance, some AAV capsid types with
reduced levels of VP1 have been reported in first generation
Figure 1. a) Shows the CDMS mass histogram measured for empty
capsids separated from AAV8 vectors with a CBA-Luc genome. The
bin width is 20 kDa. The inset shows an expanded view of the
measured peak (black line). The red line in the inset shows the
calculated histogram for homogeneous capsids consisting of only VP3
(60 copies). The width of this peak is due to the experimental
uncertainty in the m/z and charge measurements (see text). The blue
line in the inset shows the calculated histogram for capsids with a
stochastic distribution of VP1, 2, and 3 in the expected 1:1:10 ratio.
The black points in a) are a scatter plot of each ion’s charge and mass
for ions with masses greater than 3.4 MDa. There is a single charge
distribution centered around 155 elementary charges (e). b) Shows
the masses and abundances that result for a stochastic distribution of
VP1, 2, and 3 in the expected 1:1:10 ratio. The separation between the
peaks in this spectrum is too small for the peaks to be resolved in the
measured histogram in a).
Table 1. Compilation of the Expected and Measured Masses and Peak Full Width at Half Maximum (fwhm) (See Text)a
expected mass (MDa) measured mass (MDa) difference (kDa) expected fwhm (kDa) measured fwhm (kDa)
60 copies AAV8 VP3 3.586b − − 97 −
AAV8 Capsidc 3.729b 3.819 ± 16 +90 152 195 ± 8
CBA-Luc genome 1.269d 1.261 ± 21 −8 − −
AAV8/CBA-Lucc 4.998 5.080 ± 13 +82 174 208 ± 7
AAV8 Capsidc 3.729b 3.704 ± 13 −25 152 180 ± 5
155 ± 11e
scGFP Genome 1.389d 1.392 ± 13 +3 − −
AAV8/scGFPc 5.118 5.095 ± 25 −23 177 172 ± 15
aEmpty AAV8 capsids were measured after separation from CBA-Luc-containing capsids and from a sample which packaged scGFP. The
measurements for these two samples of empty capsids are grouped together with the appropriate genome in the table. bSee text for masses of VP1,
VP2, and VP3. cFor a stochastic mixture of VP1, VP2, and VP3 in an average ratio of 1:1:10. dSequence mass calculated using http://www.
bioinformatics.org/sms2/dna_mw.html. eFor the higher charge cluster of empty capsids in Figure 5.
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insect cell production systems.51−53 Newer generation systems
have altered the composition of AAV capsids to include
increased VP1 content, further supporting the notion that the
heterogeneity of AAV capsids can be modulated.53 However,
even for the sample with the reduced heterogeneity, over-
lapping charge states hindered the analysis of the m/z
spectrum, and it was only possible to identify a few capsid
compositions.
The measured peak in the empty AAV8 CDMS mass
distribution (the black line in Figure 1a) is broader than the
simulated peak for the 1:1:10 ratio and shifted to a higher mass.
From four independent measurements performed on different
days, the average mass is 3.819 ± 0.016 MDa (versus 3.729
MDa for the simulated peak) and the average width is 197 ± 8
kDa (versus 152 kDa for the simulated peak). The expected
and measured masses and peak widths are collected together in
Table 1. The difference between the measured mass and the
expected mass (2.4%) is too large to be attributed to a
systematic error in the mass measurement. A plausible
explanations for the shift and the increased peak width is
heterogeneity from salt adducts or incomplete desolvation.
However, in our previous studies of hepatitis B virus capsids15
and woodchuck hepatitis virus capsids17 the peak widths were
close to the values expected for a homogeneous sample, which
suggests that this explanation is not the main cause of the
discrepancies here. The shift and increased width could be due
to a sample that is enriched in VP1 and VP2 or more likely due
to the incorporation of small genomic DNA fragments which
are known to be present during assembly.54
Above, we described mass measurements for empty AAV8
particles. We now turn to consider the more complex scenario
of genome containing particles. Figure 2a shows an example of
the normalized mass histogram recorded for recombinant
AAV8 vectors that have packaged a single-stranded CBA-Luc
genome. The mass histogram measured for empty capsids (blue
line) is overlaid. The spectrum for the genome-containing
particles contains a major peak at around 5.1 MDa as well as a
broad distribution extending down to roughly 4.0 MDa. The
average mass of the 5.1 MDa peak is 5.080 ± 0.013 MDa (see
Table 1). The width of the peak is 208 ± 7 kDa. The expected
width is 174 kDa, so while the measured peak is slightly broader
than the measured peak for the empty capsids, it is slightly
narrower when compared to the expected peak width (120%
versus 130%).
The difference between the measured masses of the empty
particles and the genome containing particles is 1.261 ± 0.021
MDa. The expected mass of the CBA-Luc ssDNA genome with
flanking inverted terminal repeats (ITRs) is 1.269 MDa (see
Table 1). Thus, the 5.1 MDa peak is attributed to capsids that
have packaged the full length vector genome. The broad
distribution of ions below 5 MDa most likely highlights the
presence of capsids that have packaged partial ssDNA genomes.
Thus, CDMS easily resolves empty and genome-containing
particles. In addition, CDMS can differentiate particles that
have packaged partial lengths of DNA. These results are
consistent with cryo-EM analysis of AAV1 particles, which
revealed that as many as four distinct capsid structures
representing empty, partial and full virions can coexist in a
single AAV preparation.55
The results described above are also corroborated by
transmission electron micrographs of the empty capsids and
recombinant AAV8 vector preparations shown in parts b and c
of Figure 2, respectively. In Figure 2b, the donut-like structures
result from stain entering the empty capsids, while in Figure 2c
the bright uniform structures result from capsids that have
encapsidated the full genome while those with darkened
interiors (bottom right-hand corner of Figure 2c) are
attributable to capsids with a partial genome.
The difference between the measured masses of the empty
particles and the genome-containing particles (1.261 MDa) is
slightly less than the expected mass of the genome (1.269
MDa). The average mass of the empty particles is larger than
expected and if the excess mass is partly due to the
incorporation of small DNA fragments, then they would be
expected to be expelled when the genome is packaged, leading
to a smaller difference between the measured masses of the
empty particles and the genome-containing ones. The fact that
the mass distribution for the full particles is slightly less
heterogeneous than the empty ones is consistent with this
expulsion.
The molar mass of the genome was calculated assuming that
the backbone phosphates are un-ionized. In solution, the
phosphates are expected to ionize and neutrality to be retained
through counterions. The phosphate groups in the DNA
backbone are known to have a strong affinity for Na+. If all the
H+ ions associated with the backbone phosphates were replaced
by Na+ ions, the mass of the CBA-Luc genome would increase
by 90 kDa or 7.1%. The fact that the measured mass is close to
the mass expected for the genome with un-ionized backbone
phosphates suggests that the degree of incorporation of Na+, or
any other counterion, is small. Although we electrosprayed
from a low sodium buffer, the particles were not assembled in a
low sodium environment. Replacement of Na+ ions by H+
seems unlikely to occur once the particles are assembled. It is
also possible that some of the charge on the phosphate groups
is compensated by interactions with basic residues on the
capsid’s interior surface. However, there are not enough basic
residues on the interior surface to interact with all the
phosphate groups on the DNA. Estimating the number of
basic residues on the capsid interior is complicated by the fact
that only residues in VP3, and the C-termini of VP1 and VP2
that are shared with VP3, were resolved in the crystal structure
of the AAV8 capsid.56 Assuming that the unresolved N-termini
of VP1 and VP2 are completely inside the capsid, there would
still only be 720 basic residues available (according to the Φ−Ψ
Figure 2. (a) Mass histograms of separated empty (blue) and genome-
containing (black) AAV8 vectors packaging a ssDNA CBA-Luc
cassette. The histograms have been intensity normalized for
comparison. The bin widths used to generate the histograms are 20
kDa. (b and c) TEM images of the corresponding empty and full
capsids, respectively (scale bars = 100 nm).
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Explorer in VIPERdb). Even with this most favorable count, the
number of basic residues is less than one-fifth of the number
needed to compensate for the backbone phosphates. Thus,
these interactions cannot explain the absence of counterions.
To examine how well CDMS can detect compositional
heterogeneity in AAV samples, stock solutions of empty and
genome-containing capsids were mixed in a number of volume
ratios and CDMS spectra recorded. Typical results for mixtures
with empty/genome containing ratios of 1:0, 1:1, 1:15, and
1:100 are shown in Figure 3a. Figure 3b shows the fraction of
empty particles determined from the CDMS spectra plotted
against the volume fraction of empty capsid solution used in the
mixture. The relationship between the fraction of empties
determined by CDMS, FCDMS, and the volume fraction, FV, is
=
− +
F
AF
AF F 1CDMS
V
V V (1)
where A is the concentration ratio of the solutions of empty
and full capsids. Note that if the solutions had equal
concentrations, A = 1 and the equation simplifies to the linear
form, FCDMS = FV. The blue line is the fit to the data where A =
5.84, indicating that the empty solution is 5.84 times more
concentrated than the full solution.
To examine how well CDMS can quantify the different types
of AAV particles, a 1:15 mixture of the stock solutions of empty
and genome-containing capsids was spotted onto EM grids for
analysis by image counting. A representative portion of a
transmission electron micrograph of the 1:15 mixture is shown
in Figure 3c. Because of the ambiguity in assigning capsid types,
eight subjects each counted over 700 particles from 10 different
images. Subjects were asked to classify the particles as empty
(donut-like appearance), full (bright, uniform appearance), or
ambiguous (lower contrast or differential staining pattern). As
shown in Table 2, 43% of the counted particles were deemed to
contain full cargo, 30% empty capsids, and 27% ambiguous.
The assignment of a particle to a particular group depends on
the incorporation of stain. To be assigned “empty”, the particle
must acquire enough stain to attain a donut appearance. Empty
particles that acquire less stain are classified as ambiguous or
even full. Thus, the number of empty particles may be
underestimated. The ambiguous particles could be under-
stained empty particles. On the other hand, the CDMS
measurements show that there are a significant number of
partially filled particles, and so the ambiguous particles could
also be stained partially filled particles. A bright uniform
appearance suggests a full particle; however, this appearance
could also be due to particles that are partially full (or empty)
that have not picked up enough stain. Thus, the number of full
particles may be overestimated.
For comparison, a single CDMS histogram of the same
empty/full capsid mixture used for EM analysis was fit with a
series of Gaussians with widths corresponding to that of the
empty peak. The areas underneath the Gaussians were used to
determine the relative abundances of each particle type. Any
Gaussian not associated with the empty or full capsids were
assigned as ambiguous or to capsids packaging partial genomes.
As shown in Table 2, 42% of the detected ions had a mass that
corresponded to the capsid plus the full-length genome; 29% of
ions had a mass between that of an empty and full particle; and
29% of ions had a mass corresponding to an empty capsid.
It is evident from Table 2 that the relative abundances
determined by CDMS are in good agreement with those
obtained from EM particle counting. The values in parentheses
in Table 2 are the standard deviation from multiple analyses of
the same data set. The standard deviations for the EM-derived
data are large and reflect the high degree of subjectivity
associated with manually classifying particle types. On the other
hand, CDMS is able to unambiguously differentiate between
empty particles, particles containing a partial genome, and
particles containing the full genome. The measurement time for
CDMS was around 2 h, which is longer than it takes to spot
grids and measure EM images. On the other hand, it takes a few
minutes to generate a mass histogram from the CDMS data,
while the manual particle counting of multiple EM images we
performed to generate the data given in Table 2 took more
than an hour per person. However, the processing of the EM
images could be automated, and this would dramatically reduce
the time needed to process the images.
There are two main sources of discrimination associated with
ion detection in CDMS. First, for ions that carry a small charge
there is the possibility that the signal is lost in the noise.
Figure 3. Empty and genome containing capsid solutions mixed in
ratios of 1:0, 1:1, 1:15, and 1:100 v/v and analyzed by CDMS.
Individual CDMS histograms are stacked in panel a. The fraction of
empty capsids determined by CDMS is plotted against the volume
fraction of the empty capsid solution in panel b. The blue line (see
text) is the best fit to the data using eq 1 (see text). A representative
micrograph of the 1:15 v/v empty/genome containing mixture is
shown in panel c. The image shows empty capsids (blue arrow), full
capsids (red arrow), and partially filled capsids (white arrow) (scale
bar = 100 nm).
Table 2. Comparison of the AAV Particle Types Determined
by Electron Microscopy with Manual Image Counting (EM)
and Charge Detection Mass Spectrometry (CDMS)a
full ambiguous/partial empty
EM 0.43 (±0.16) 0.27 (±0.15) 0.30 (±0.16)
CDMS 0.421 (±0.004) 0.288 (±0.006) 0.291 (±0.002)
aThe numbers indicate the fractions of the different particle types in
the 1:15 v/v mixed sample (see text). Numbers in parentheses are
standard deviations for multiple analyses of the same data set.
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However, with the instrument and data analysis scheme
employed here the detection efficiency is expected to be
100% for trapped ions with more than 10 charges.39 Therefore,
low detection efficiency is not expected to be an issue here,
where the ions usually have more than 100 charges. The second
source of discrimination is that the probability of being trapped
depends on the ion velocity. Faster ions spend less time in the
trap and hence they have a lower probability of being trapped.
Because the ion energy is known and constant, it is
straightforward to correct for mass discrimination resulting
from different ion velocities, the ions are weighted by the
square root of their m/z (which is directly measured for each
ion). This correction has been included in Table 2. The good
agreement between the particle counting and CDMS values in
Table 2 points to a lack of significant mass discrimination in the
relevant mass range, after the correction for the ion velocity has
been taken into account. Since the ion velocity is inversely
proportional to the square root of the m/z, the detection
efficiency for light ions is less than for heavy ions in the
continuous trapping mode used here. This is usually beneficial
because light ions are generally much more abundant than
heavy.
For comparison with the results presented above for the
single-stranded genome we used CDMS to analyze AAV
particles containing a self-complementary genome, in this case
scGFP, which is 4.174 kb long. Figure 4a shows a representative
CDMS mass histogram. There are four main features: two
narrow, intense peaks at ∼3.7 and ∼5.1 MDa; a comparably
intense but broader distribution between 4 and 5 MDa; and a
small peak at ∼5.6 MDa. The peak at ∼3.7 MDa (average mass
3.704 ± 0.013 MDa) is close to the mass expected for the
empty capsid (3.729 MDa, see Table 1). In this case, the
average mass is slightly less than the measured mass. The
difference is small and could be due to the amount of VP1 and
VP2 in this sample being slightly less than in the expected
1:1:10 ratio. The average mass of the capsid separated from the
CBA-Luc-containing capsids was 3.819 MDa, so these results
confirm that AAV capsids from different sources can have
slightly different masses.
The average mass difference between the two major peaks in
Figure 4a is 1.392 ± 0.013 MDa. This is in good agreement
with the sequence mass of the scDNA (1.389 MDa), so the
peak near 5.1 MDa is assigned to the capsid with the full sc
genome. A representative micrograph (Figure 4b) is shown
below the mass histogram. The image confirms the presence of
empty and full particles. The sequence mass for the scDNA
given above was calculated for un-ionized DNA so the close
agreement with the measured genome mass (the differences
between the masses of the empty and full particles) indicates
that the scDNA is mainly packaged without counterions. We
reached a similar conclusion for the ssDNA genome discussed
above.
The broad distribution between 4 and 5 MDa in Figure 4a is
attributed to partially filled capsids. The peak in this
distribution occurs roughly halfway between the peaks due to
the empty and full capsids indicating a propensity to package
truncated genomes averaging approximately half of the full
genome length. This indicates a preference for cleaving the
genome near the hairpin that joins the two self-complementary
segments. The peak attributed to packaging of a partial genome
is broad indicating that there is some variability in where the
genome is cleaved relative to the hairpin. In contrast, for single-
stranded CBA-Luc (Figure 2a), the distribution of partially
packaged genomes is broader and does not show a preference
for packaging half the genome.
In Figure 4a, approximately 35% of the capsids are empty,
23% packaged the full genome, and nearly 42% of the capsids
have masses that lie between the empty and full capsids. We
found that the amount of monomeric and self-complementary
genomes packaged can vary significantly for different samples
with as little as 5% of the capsids containing the full genome in
one case.
A scatter plot of z vs m for the scGFP-filled capsids is shown
in Figure 5a. Each point represents an ion. There are clusters of
ions associated with empty (∼3.7 MDa), partially full (4−5
MDa), and full capsids (∼5.1 MDa). There are two clusters for
the empty particles: the main cluster centered at ∼155 e and a
more-diffuse cluster centered at ∼135 e. Note that the lower-
charge cluster is slightly heavier, on average, than the higher-
charge cluster. Similar lower-charge clusters of ions are absent
for the partially filled and full capsids. The higher-charge cluster
of empty particles and the clusters due to the partially full and
the full capsids have similar average charges that increase
slightly with mass (from ∼155 to to ∼160 e). Finally, the small
cluster of ions near 5.6 MDa has a higher average charge of
∼195 e.
The mechanism by which ions are produced by electrospray
depends on their size. The large ions studied here are expected
to be generated by the charge residue mechanism.57,58 Here,
the water droplet containing the analyte evaporates away,
leaving the ion with a charge close to the Rayleigh limit for a
water droplet with the same radius as the analyte. Inspection of
Figure 5 shows that the main clusters of ions associated with
the empty, partial, and full capsids have similar charges
indicating that the genome and partial genome are packaged
Figure 4. (a) Mass histogram for AAV8 packaging an scGFP genome
and (b) electron micrograph of the same sample (scale bar = 200 nm).
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inside the capsid. If some of the genome extended outside the
capsid the charges would be higher. Indeed this might provide
an explanation for the tail of highly charged ions that extend
from the cluster due to the full particles (see Figure 5a).
There are two distinct charge state distributions for the
empty capsids in Figure 5. This behavior has been observed for
other empty capsids by CDMS where it was attributed to the
compaction of some of the capsids during the electrospray
process.17 The absence of low charge clusters for the partial and
full capsids in Figure 5 can be attributed to the presence of the
genome, which presumably helps the capsids resist compac-
tion.59 Evidently, even a partial genome is enough to prevent
compaction. A low charge cluster of ions was also not observed
in the charge versus mass scatter plot for the empty particles
separated from AAV8 vectors with a CBA-Luc genome (Figure
1). The scatter plot for these ions shows a single cluster
centered at ∼155 e. However, the masses of the separated
AAV8 particles are significantly larger than expected for empty
particles (see Table 1), leading to the suggestion that they may
contain some small DNA fragments.
The small peak at ∼5.55 MDa in Figure 4a is probably due to
an impurity. If it is attached to the full capsid then its mass is
around 416 ± 25 kDa. The fact that the ions in this peak have
significantly higher average charge than the full particles (see
Figure 5) suggests that the impurity is outside the capsid where
it increases the average radius of the ion. Note that there is no
evidence for the same impurity attached to the outside of the
empty capsid. Such a low abundance impurity attached to the
empty capsid would be difficult to detect in the mass
distribution shown in Figure 4a; however, it would be easy to
detect in the charge versus mass scatter plot.
Since the average charges on the empty, partial, and full
particles are similar, it is possible that useful information on
their relative abundances could be obtained from the m/z
distribution that is accessible from conventional mass
spectrometry methods, even without charge state resolution.
The red diagonal lines in the charge versus mass plot (Figure
5a) show lines of constant m/z. The m/z histogram is shown in
Figure 5b. There are peaks at 24, 28, and 32 kDa. Inspection of
Figure 5a shows that these are due to empty, partial, and full
capsids. Therefore, the m/z spectrum alone can reveal some
information about the composition. However, the components
are more poorly resolved and their relative abundances are
different from in the mass distribution. Inspection of Figure 5a
reveals the origin of the difference. The low charge component
of the empty capsids has m/z values (∼28 kDa) similar the
partially filled particles, as does the high mass component at
∼5.55 MDa. Thus, the m/z distribution underestimates the
empty capsids, overestimates the partial, and cannot detect the
high mass impurity.
In conclusion, CDMS can rapidly establish the purity of AAV
vector preparations by resolving the particles into empty,
partial, and full subpopulations. The sc AAV vector preparation
appears to contain particles with partially truncated genomes
averaging at half of the genome length. The close agreement
between CDMS results and electron microscopy with manual
particle counting confirms expectations that mass discrim-
ination is small in the relevant mass range (after correcting for
the ion velocity). The single particle resolution of AAV vector
preparations by CDMS will enable rapid screening and quality
testing of clinical samples. Because the empty, partial, and full
capsids have similar charges (as expected from the charge
residue model) it is possible to obtain some abundance
information from the m/z spectra alone, even without charge
state resolution. However, CDMS provides much more reliable
information, and low abundance species can be detected by
dispersing the ions in two dimensions (charge and mass). The
differences between the masses of the empty and full particles,
for both the ss and sc genomes, indicate that the DNA is
packaged without counterions.
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